{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}],"title":"Stringent Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"9"}]}],"title":"Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"29"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}],"title":"Minimal Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"72"}],"units":"Participants"}],"description":"Stringent Complete Response-Complete Response and normal free light chain ration and no clonal cells in bone marrow Complete Response- no monoclonal protein (mp) in blood, no serum or urine mp, less than 5% plasma cells in bone marrow Very Good Partial Response-more than 90% decrease in mp and urine protein Partial Response- over 50% decrease in serum mp Stable Disease- less than 25 percent decrease of monoclonal protein Progressive Disease- 25% increase compared to lowest value of serum mp, urine mp, no measurable mp","groups":[{"description":"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 milligram per square meter (mg/m\\^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG000","title":"100 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG001","title":"300 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Placebo administered once IV on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG002","title":"Placebo Comparator: Placebo + Dexamethasone + Bortezomib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline to Objective Disease Progression or Initiation of New Cancer Treatment (28 Months)","title":"Participants With Best Overall Response (BOR) in Each Category","type":"SECONDARY","unitOfMeasure":"Participants"}